News & Updates
Showing Respirology articles
Showing

Does radiotherapy improve survival in NSCLC patients with cachexia?
Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.

Sitra + nivo slightly better than docetaxel in advanced NSCLC
Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.

Amivantamab plus chemo improves survival in advanced NSCLC
Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.






